A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

NCT04078386 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Sjögren's Syndrome

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: RC18 240 mg
BIOLOGICAL: RC18 160 mg

Sponsor

RemeGen Co., Ltd.